Phytoestrogens for vasomotor menopausal symptoms

University of Auckland, O&G FMHS, Grafton Rd, Private Bag 92019, Auckland, New Zealand, 1142.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 02/2007; DOI: 10.1002/14651858.CD001395.pub3
Source: PubMed

ABSTRACT Vasomotor symptoms, such as hot flushes and night sweats, are very common during the menopausal transition. Hormone replacement therapy has traditionally been used as a very effective treatment but concerns over increased risks of some chronic diseases have markedly increased the interest of women in alternatives. Some of the most popular of these are treatments based on foods or supplements enriched with phytoestrogens, plant-derived chemicals that have oestrogenic action.
To assess the efficacy, safety and acceptability of foods and supplements based on high levels of phytoestrogens for reducing hot flushes and night sweats in postmenopausal women.
Searches were undertaken of the following electronic databases: the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of randomised trials, Cochrane Register of Controlled Trials (CENTRAL) (March 2007), MEDLINE (1966 to March 2007), EMBASE (1980 to March 2007), AMED (1985 to March 2007), PsycINFO (1986 to March 2007) and CINAHL (1982 to March 2007). Attempts were made to access grey literature by letters to pharmaceutical companies and searches of ongoing trial registers. Reference lists of included trials were also searched.
Studies were included if they were randomised, had peri- or postmenopausal participants with vasomotor symptoms, a duration of at least 12 weeks and where the intervention was a food or supplement with high levels of phytoestrogens (and not combined with other herbal treatments). Trials of women who had breast cancer or a history of breast cancer were excluded.
Selection of trials, data extraction and quality assessment were undertaken by at least two authors. Most of the trials were too dissimilar to combine in meta-analysis and their results are provided in table format. Studies were grouped into broad categories: dietary soy, soy extracts, red clover extracts and other types of phytoestrogen. Five trials used Promensil, a red clover extract; these trials were combined in a meta-analysis and summary effect measures were calculated.
Thirty trials comparing phytoestrogens with control met the inclusion criteria. Very few trials had data suitable for combining in meta-analysis. Of the five trials with data suitable for pooling that assessed daily frequency of hot flushes, there was no significant difference overall in the frequency of hot flushes between Promensil (a red clover extract) and placebo (WMD=-0.6, 95% CI -1.8 to 0.6). There was no evidence of a difference in percentage reduction in hot flushes in two trials between Promensil and placebo (WMD=20.2, 95% CI -12.1 to 52.4). Individual results from the remaining trials were compared. Some of the trials found that phytoestrogen treatments alleviated the frequency and severity of hot flushes and night sweats when compared to placebo but many of the trials were of low quality and were underpowered. There was a strong placebo effect in most trials with a reduction in frequency ranging from 1% to 59% with placebo. There was no indication that the discrepant results were due to the amount of isoflavone in the active treatment arm, the severity of vasomotor symptoms or trial quality factors. There was also no evidence that the treatments caused oestrogenic stimulation of the endometrium (an adverse effect) when used for up to two years.
There is no evidence of effectiveness in the alleviation of menopausal symptoms with the use of phytoestrogen treatments.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key pointsSeveral non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required.
    SpringerPlus 12/2015; 4(1). DOI:10.1186/s40064-015-0808-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The present study is aimed at determining the effect of supplementing the diet of postmenopausal women with soy isoflavones on blood pressure and hormonal levels and providing relief from symptoms. Method: This research was conducted in Imam Khomeini Hospital, Ahvaz, Iran. In this double-blind experimental controlled study, 61 postmenopausal women were randomly assigned to either an experimental group (soy isoflvone, n = 30) or control group (placebo, n = 31). The subjects in the experimental group were given a supplementation of 33 g of soy in the form of biscuits that contained approximately 54 mg isoflavones for a period of 8 weeks. Results: Soy isoflavones supplementation made a significant difference in the severity and intensity of symptoms as determined by the Kuppermann index. On supplementation with soy the intensity of symptoms among the subjects decreased significantly and the mean total score from 26.8% at pre phase decreased to 9.38% at post phase (p < 0.001). In the present study, the level of follicular stimulating hormone (FSH) and luteinizing hormone (LH) in the experimental group decreased after intervention with soy. This reduction in FSH and LH was highly significant as tested by repeated measures analysis of variance (ANOVA; p < 0.001). After intervention with soy, a slight reduction in systolic and diastolic blood pressure was recorded in the experimental group, indicating the beneficial effect of soy isoflavones on regulating blood pressure. Conclusion: This study suggests that soy supplementation could be recommended as an alternative therapy to hormone replacement therapy for control of postmenopausal symptoms.
    Journal of the American College of Nutrition 02/2015; 34(1):1-7. DOI:10.1080/07315724.2013.875434 · 1.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Isoflavones and their metabolites are termed phytoestrogens because they bind to estrogen receptors, although weakly compared to physiologic estrogens. Soybean is the main source of phytoestrogens. Several recent reviews concluded that there is no evidence that phytoestrogens relieve menopausal symptoms better than placebo. At the same time, some studies suggest their efficacy. In theory, the use of phytoestrogens for hormone replacement appears irrational: biological action of estrogens is receptor-mediated; the question is therefore, why the vegetable analogues should be used instead of physiological hormones optimally complementary to the receptors. Apparently, the problem should be seen within the scope of placebo marketing under the guise of evidence-based medications. For example, a supposed anti-atherogenic effect of phytoestrogens was confirmed by doubtful experiments with cell cultures, which are discussed here. Furthermore, there is a contradiction: phytoestrogens are supposed to compensate for estrogen deficiency in menopause; but at the same time, their estrogenic potential does not prevent the widespread use of soy for infant food and other foodstuffs. Environmentally relevant doses of phytoestrogens have impacts on ovarian differentiation, fertility and genderrelated behavior in animals. In conclusion, the beneficial and potentially harmful effects of phytoestrogens should be clarified by independent research, which can be of importance for the future of the soybean in agriculture.
    01/2013; 2(2):67-72. DOI:10.5455/jice.20130513122619

Full-text (2 Sources)

Available from
Jun 2, 2014